Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference

Core Points - Nyxoah will participate in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, presenting at 2:00pm ET via webcast [1][2] - The company focuses on developing innovative treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation [3] - Nyxoah's flagship product, Genio®, is a battery-free hypoglossal neuromodulation device that has shown best-in-class outcomes for reducing OSA burden [3] Company Overview - Nyxoah aims to address the needs of the billion people suffering from OSA by providing breakthrough treatment options [3] - The Genio® system received its European CE Mark in 2019 following the successful BLAST OSA study [4] - The company has completed two successful IPOs, one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021 [4] - Following positive outcomes from the BETTER SLEEP study, Nyxoah expanded its therapeutic indications to include Complete Concentric Collapse (CCC) patients, which are currently contraindicated in competitors' therapies [4] - The company also announced positive outcomes from the DREAM IDE pivotal study, which is aimed at obtaining FDA approval for U.S. commercialization [4]